Inspire Medical Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 04:28 pm EST
Share
Inspire Medical Systems, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 153.3 million compared to USD 109.19 million a year ago. Net loss was USD 8.54 million compared to USD 16.85 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.6 a year ago.
For the nine months, sales was USD 432.29 million compared to USD 269.96 million a year ago. Net loss was USD 35.92 million compared to USD 48.03 million a year ago. Basic loss per share from continuing operations was USD 1.23 compared to USD 1.73 a year ago.
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patientâs breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers.
INSPIRE MEDICAL SYSTEMS, INC. 
